ATE280235T1 - Plasmid zur herstellung von crm-protein und diphtherie-toxin - Google Patents

Plasmid zur herstellung von crm-protein und diphtherie-toxin

Info

Publication number
ATE280235T1
ATE280235T1 AT94101770T AT94101770T ATE280235T1 AT E280235 T1 ATE280235 T1 AT E280235T1 AT 94101770 T AT94101770 T AT 94101770T AT 94101770 T AT94101770 T AT 94101770T AT E280235 T1 ATE280235 T1 AT E280235T1
Authority
AT
Austria
Prior art keywords
plasmid
diphtheria toxin
crm197
protein
novel
Prior art date
Application number
AT94101770T
Other languages
English (en)
Inventor
Benjamin J Metcalf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE280235T1 publication Critical patent/ATE280235T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94101770T 1993-03-05 1994-02-07 Plasmid zur herstellung von crm-protein und diphtherie-toxin ATE280235T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2728393A 1993-03-05 1993-03-05

Publications (1)

Publication Number Publication Date
ATE280235T1 true ATE280235T1 (de) 2004-11-15

Family

ID=21836767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94101770T ATE280235T1 (de) 1993-03-05 1994-02-07 Plasmid zur herstellung von crm-protein und diphtherie-toxin

Country Status (21)

Country Link
US (1) US5614382A (de)
EP (1) EP0616034B1 (de)
JP (1) JP4144813B2 (de)
KR (1) KR100316004B1 (de)
CN (1) CN1100757A (de)
AT (1) ATE280235T1 (de)
AU (1) AU686126B2 (de)
BR (1) BR1100634A (de)
CA (1) CA2116914C (de)
CZ (1) CZ39394A3 (de)
DE (1) DE69434079T2 (de)
DK (1) DK0616034T3 (de)
ES (1) ES2231770T3 (de)
FI (1) FI112090B (de)
HU (1) HUT71320A (de)
IL (1) IL108822A (de)
NO (1) NO313758B1 (de)
NZ (1) NZ260027A (de)
PT (1) PT616034E (de)
SK (1) SK24094A3 (de)
ZA (1) ZA941548B (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032137A2 (en) * 1995-04-14 1996-10-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of inducing immune tolerance using immunotoxins
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
WO1998039425A2 (en) * 1997-03-05 1998-09-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectors and methods for expression of mutant proteins
JP2002501484A (ja) 1997-03-05 2002-01-15 アメリカ合衆国 免疫毒素および免疫寛容を誘導する方法
US6676943B1 (en) * 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
CN1086945C (zh) * 1997-06-03 2002-07-03 胡章英 白喉口服液
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
KR101157694B1 (ko) 2003-12-17 2012-06-20 와이어쓰 엘엘씨 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
JP4696079B2 (ja) 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
EP3311836A1 (de) 2005-04-08 2018-04-25 Wyeth LLC Multivalente pneumokokken- polysaccharidproteinkonjugatzusammensetzung
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
JP5155306B2 (ja) 2006-05-31 2013-03-06 ルチアナ バロンチニ ジフテリア毒に免疫学的に関連したタンパク質分子の薬学的使用
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CN101265288B (zh) * 2007-03-13 2012-03-21 齐鲁制药有限公司 Crm197突变体的纯化方法
US20120052088A1 (en) 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
AU2010201410B2 (en) * 2010-03-30 2015-04-30 Pelican Technology Holdings, Inc. High level expression of recombinant CRM197
PL2575870T3 (pl) 2010-06-04 2017-05-31 Wyeth Llc Preparaty szczepionek
EP2575868A1 (de) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
KR101895768B1 (ko) * 2011-06-01 2018-09-07 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
CN102766647A (zh) * 2012-07-25 2012-11-07 天津康希诺生物技术有限公司 在白喉杆菌中稳定复制的表达载体及含该载体的白喉杆菌
DK2885007T3 (en) 2012-08-16 2018-12-03 Pfizer Methods for glycoconjugation and compositions
RU2015106791A (ru) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
JP6502262B2 (ja) 2012-12-20 2019-04-17 ファイザー・インク 糖複合化方法
CN111499679B (zh) 2013-01-04 2021-07-06 台湾浩鼎生技股份有限公司 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN104140972B (zh) * 2013-05-07 2018-01-23 上海惠盾生物技术有限公司 白喉毒素突变体crm197的制备方法
EP3511161A1 (de) 2013-08-26 2019-07-17 Corning Incorporated Laminierte struktur
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
PL3096786T3 (pl) 2014-01-21 2021-11-08 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
CN110859957B (zh) 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
DK3099800T3 (da) 2014-01-31 2021-01-11 Fina Biosolutions Llc Ekspression og oprensning af crm197 og beslægtede proteiner
ES2701169T3 (es) 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CA2968491C (en) 2014-11-20 2023-09-26 Biological E Limited Codon optimized polynucleotide for high level expression of crm197
HUE062499T2 (hu) 2015-01-15 2023-11-28 Pfizer Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MY182282A (en) 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US11147863B2 (en) 2015-06-23 2021-10-19 Biological E Limited Multivalent pneumococcal conjugate vaccine
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
JP2019512233A (ja) 2016-03-10 2019-05-16 ザ・ジョンズ・ホプキンス・ユニバーシティー 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
US11191822B2 (en) 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
EP3269385A1 (de) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
CA3031799A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ752348A (en) 2016-09-30 2022-11-25 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4656208A3 (de) 2017-01-31 2026-03-04 Merck Sharp & Dohme LLC Verfahren zur herstellung von polysaccharid-protein-konjugaten
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
KR101908590B1 (ko) 2017-02-01 2018-10-16 (주)포바이오코리아 Crm197의 용해성 단백질 발현 및 정제 방법
CA3052621A1 (en) 2017-02-03 2018-08-09 Schadeck, Eva Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
MX2019009869A (es) 2017-02-24 2019-10-02 Merck Sharp & Dohme Formulaciones de vacunas de conjugado de neumococos.
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
SMT202200356T1 (it) * 2017-04-22 2022-11-18 Biological E Ltd Un metodo migliorato per produzione ad alto livello di crm
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
ES3058336T3 (es) 2017-12-06 2026-03-10 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos
EP3749357A4 (de) 2018-02-05 2022-04-20 Sanofi Pasteur, Inc. Polyvalente pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
KR102475419B1 (ko) * 2018-07-16 2022-12-07 주식회사 유바이오로직스 Crm197을 고농도로 발현하는 코리네박테리움 균주
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2021003358A (es) 2018-09-23 2021-05-27 Biological E Ltd Polisacaridos capsulares purificados de streptococcus pneumoniae.
CN109100517A (zh) * 2018-10-08 2018-12-28 武汉生命科技股份有限公司 一种用于检测白喉抗体的抗原蛋白、试剂盒及制备方法
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
PH12022550110A1 (en) 2019-07-31 2022-12-12 Sk Bioscience Co Ltd Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20230000966A1 (en) 2019-11-01 2023-01-05 Pfizer Inc. Escherichia coli compositions and methods thereof
CN119371566A (zh) 2020-02-21 2025-01-28 辉瑞公司 糖类的纯化
BR112022014555A2 (pt) 2020-02-23 2022-09-20 Pfizer Composições de escherichia coli e métodos das mesmas.
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP3919076A1 (de) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
KR20230056727A (ko) 2020-08-26 2023-04-27 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP7804673B2 (ja) 2020-11-10 2026-01-22 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
KR20220102871A (ko) 2021-01-14 2022-07-21 (주)셀트리온 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN116942804A (zh) 2022-04-19 2023-10-27 上海瑞宙生物科技有限公司 多价肺炎球菌多糖结合疫苗的成分及其应用
CA3256617A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
TW202432182A (zh) 2022-10-24 2024-08-16 瑞士商愛杜西亞製藥有限公司 對抗克雷伯氏肺炎桿菌之疫苗
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (de) 2022-11-22 2025-10-01 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
AU2023403045A1 (en) 2022-12-01 2025-06-12 Pfizer Inc. Pneumococcal conjugate vaccine formulations
KR20250120353A (ko) 2022-12-08 2025-08-08 이도르시아 파마슈티컬스 리미티드 클렙시엘라 뉴모니아에의 백신
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20252774A1 (es) 2023-03-30 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121532194A (zh) 2023-05-18 2026-02-13 默沙东有限责任公司 用于肺炎球菌疫苗的化合物及佐剂制剂
KR20260015203A (ko) 2023-05-19 2026-02-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025106603A1 (en) 2023-11-16 2025-05-22 Merck Sharp & Dohme Llc Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025174398A1 (en) 2024-02-14 2025-08-21 Merck Sharp & Dohme Llc 26-valent pneumococcal conjugate vaccines and methods of use thereof
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2026013167A1 (en) 2024-07-11 2026-01-15 Idorsia Pharmaceuticals Ltd Pharmaceutical composition comprising clostridioides difficile vaccine
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH660375A5 (it) * 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
FR2549855B1 (fr) * 1983-07-29 1987-03-27 Grp Genie Genetique Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues

Also Published As

Publication number Publication date
NO940774L (no) 1994-09-06
NO313758B1 (no) 2002-11-25
FI941050L (fi) 1994-09-06
ZA941548B (en) 1994-10-03
CA2116914A1 (en) 1994-09-06
PT616034E (pt) 2005-02-28
AU686126B2 (en) 1998-02-05
ES2231770T3 (es) 2005-05-16
IL108822A0 (en) 1994-06-24
CZ39394A3 (en) 1995-02-15
BR1100634A (pt) 1999-12-07
KR940021731A (ko) 1994-10-19
EP0616034B1 (de) 2004-10-20
CA2116914C (en) 2005-02-08
NO940774D0 (no) 1994-03-04
EP0616034A3 (en) 1996-10-16
DK0616034T3 (da) 2005-02-21
IL108822A (en) 2004-09-27
FI941050A0 (fi) 1994-03-04
JP4144813B2 (ja) 2008-09-03
HU9400657D0 (en) 1994-05-30
KR100316004B1 (ko) 2002-02-19
DE69434079D1 (de) 2004-11-25
JPH06292593A (ja) 1994-10-21
CN1100757A (zh) 1995-03-29
EP0616034A2 (de) 1994-09-21
SK24094A3 (en) 1995-03-08
NZ260027A (en) 1996-03-26
FI112090B (fi) 2003-10-31
AU5759594A (en) 1994-09-08
DE69434079T2 (de) 2005-02-24
US5614382A (en) 1997-03-25
HUT71320A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
ATE280235T1 (de) Plasmid zur herstellung von crm-protein und diphtherie-toxin
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
DE69330518D1 (de) Dna, die aspartokinase iii-mutanten kodiert und ihre verwendung zur herstellung von l-threonin durch fermentation
RU2003128977A (ru) Способы секреторной продукции белков
DE88166T1 (de) Verfahren zum exprimieren eines gens.
IL103057A0 (en) Dna sequences encoding gelonin polypeptide
DE69014046D1 (de) Verzweigungsenzym und dessen Verwendung.
ATE140971T1 (de) Verfahren zur herstellung von clavulanic säure
AU3475495A (en) Process for producing recombinant proteins, plasmids and modified cells
DE69224269D1 (de) Biosynthetisches Verfahren zur Herstellung von Protein
ATE334203T1 (de) Verfahren zur herstellung von sekundären metaboliten
ATE111528T1 (de) Optimierte fermentationsverfahren zur herstellung von fremdproteinen in e.coli.
CA2121481A1 (en) Expression of polypeptides in e.coli under control of the e.coli mdh-gene promoter
RU94007083A (ru) Способ получения дифтерийного токсина или белка crm, плазмиды, микроорганизма
ATE190653T1 (de) Verfahren zur herstellung von rekombinanten und synthetischen peptiden und deren verwendung
ATE346941T1 (de) Protein-disulfidisomerase-gen eines methylotrophen hefestammes
KR970021294A (ko) 유기산 생성이 억제된 대장균 변이주

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0616034

Country of ref document: EP

REN Ceased due to non-payment of the annual fee